Edwards Lifesciences (EW)
Health Care · medical devices - cardiovascular · NYSE
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.
What Edwards Lifesciences does
Edwards Lifesciences focuses on innovations for structural heart disease and critical care monitoring. The company specializes in developing technologies for patients with cardiovascular disease, including transcatheter heart valve replacement and repair technologies.
Themes: structural heart disease, heart valve replacement, cardiovascular health, medical technology innovation
Fundamentals
- Price$84.24 as of 2026-10-08 close
- Market cap$48.6B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+11.2% 2025-10-08 close $75.74 → 2026-10-08 close $84.24
- P/E48.74 as of 2026-10-08
- Net margin+17.7% FY2025, SEC XBRL
- Gross margin+78.0% FY2025, SEC XBRL
- ROE+10.4% FY2025, SEC XBRL
- Debt / equity0.06 as of 2026-09-03
- Revenue growth (YoY)+14.6% as of 2026-09-03
- Revenue CAGR (3y)+10.8% SEC XBRL
- Beta0.55 as of 2026-09-03
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
How EW compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
EW is not currently in any published Top 10 list. Its scores are below.
Top 10 score
60.0 #235 of 1,379 scored · #30 of 151 in Health Care
Financial health 81st (debt to equity 0.1, free cash flow margin 22%) and trend 67th (a "golden cross" — its 50-day average is above its 200-day); weakest is valuation (30th, price to earnings 48.7, price to book 4.6).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Edwards Lifesciences looks technically
Edwards Lifesciences (EW) is trading 1.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 368 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-07-28, breaking below its recent trading range.
Trend
8
| Distance from the 200-day | it is trading 1.0% below its 200-day average, the long-term trend line — a long-term downtrend | -1.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $88.65 | $88.65 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $85.12 | $85.12 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 89.7. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 368 trading days ago — a "golden cross", a bullish long-term signal | 368 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 13.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 39.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($82.46 to $89.66) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 24.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $96.29 | $96.29 |
|---|---|---|
| From the 52-week high | it is 12.5% below its 52-week high (its highest price of the past year) | -12.5% |
| Above the 52-week low | it is 16.5% above its 52-week low (its lowest price of the past year) | +16.5% |
| Below the 52-week high | it is 12.5% below its highest point of the past year | 12.5% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-07-28, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $131.73 (set on 2021-12-30) | $131.73 |
| Given back of the 52-week move | over the past year its closes ranged ($72.65 to $95.18), and it has given back around half of its rise from last year’s low — 49% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $80.54 to $81.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 48.6% |
| From the all-time high | it is 36.1% below its all-time high | -36.0% |
| Nearest price level | it is trading 1.6% above a support level at $82.91 — a price it turned at 8 times since 2025-07-25, most recently on 2026-09-11. Since 2024-10-08 it has 8 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.6% |
| All-time low | its lowest closing price on record is $1.00 (set on 2000-11-01) | $1.00 |
| Above the all-time low | it is 8324.0% above its all-time low | +8,324% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.17 between its high and its low — about 2.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.17 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $83.76 and $89.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $83.76 – $86.63 – $89.51 |
| Typical daily range (% of price) | its price moves about 2.6% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges below its 200-day average price (1.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.97× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.0% since the prior reading | +1.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.03 toward buy |
Candlestick patterns
1
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Gap filled | a 5.0% gap up opened on 2026-07-24 has been "filled" 53 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 53 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -3.43% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.9 percentage points (the stock lost 2.9% while the market gained 1.0%) | -3.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.9 percentage points (the stock lost 10.0% while the market gained 3.8%) | -13.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.7 percentage points (the stock gained 3.8% while the market gained 17.5%) | -13.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 3.8 percentage points (the stock gained 11.2% while the market gained 15.0%) | -3.8% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.1% of the share price, which is taken to mean a barrier that gives way easily. | -5.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $84.73 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -0.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-07-23 (its 8-K), so the typical buyer over that stretch is under water. That average is $87.60 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | -3.8% |
Double bottom, bullish — forming · entry $93.66 · 53 sessions in
Symmetrical triangle, either side — broke down · the lower entry $85.34 · 67 sessions in
Price levels it has turned at before
EW last closed at $84.24 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $82.91 | Support | 1.6% below the last close | turned there 8 times · 2025-07-25 to 2026-09-11 |
| $85.62 | Resistance | 1.6% above the last close | turned there twice · 2026-01-22 to 2026-05-01 |
| $87.38 | Resistance | 3.7% above the last close | turned there six times · 2025-10-31 to 2026-03-02 |
| $80.73 | Support | 4.2% below the last close | turned there four times · 2025-08-28 to 2026-07-27 |
| $89.19 | Resistance | 5.9% above the last close | turned there three times · 2026-07-24 to 2026-09-16 |
| $78.64 | Support | 6.7% below the last close | turned there four times · 2025-05-28 to 2025-10-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $89.70.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 15 trading days, since 2026-09-18.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market · Trading at this year’s average price paid (anchored VWAP) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.59 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$101.96 range $84.00 – $110.00; median $102.50
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EW
- Consensus EPS estimate$0.7369 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.00014 (+0.0%) from $0.7368, on 2026-09-03, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to successfully innovate and market new products","Unsuccessful clinical trials or procedures","Inability to obtain governmental reimbursement or reductions in reimbursement levels"]
What changed in the latest 10-Q
AI-assisted comparison of EW's 10-Q filed 2026-08-04 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds a paragraph stating that in May 2026 the company amended several agreements with a medical device company (the "Consolidated VIE"), became its primary beneficiary, and consolidated it in the condensed consolidated financial statements as of May 2026.
- Newer filing adds a statement that the results of the Consolidated VIE have been included in the condensed consolidated financial statements from the amendment date.
- Newer filing extends the reporting period discussion from three months (first quarter) to six months (first half of 2026), including six-month net sales figures.
- Newer filing adds six-month regional net sales data (United States $1,941.1M, Europe $882.2M, Japan $187.0M, Rest of World $379.3M, Outside U.S. $1,448.5M, Total $3,389.6M) and corresponding percentage changes.
- Newer filing adds six-month product group net sales data (TAVR $2,455.6M, TMTT $373.7M, Surgical $560.3M, Total $3,389.6M) and corresponding percentage changes.
- Newer filing adds a discussion of TAVR sales for the six months ended June 30, 2026, including foreign currency impact of $40.4M for the six-month period.
- Newer filing adds discussion of gross profit for the six months ended June 30, 2026, noting the decrease in gross profit as a percentage of sales was driven primarily by foreign currency rate fluctuations partially offset by lower manufacturing expenses.
- Newer filing adds discussion of diluted earnings per share for the six months ended June 30, 2026, noting the decrease was driven by an increase in tax expense partially offset by operational performance.
- Removed:
- Older filing contains a discussion of gross profit for the three months ended March 31, 2026, noting the decrease in gross profit as a percentage of sales was driven by negative 0.3 percentage point impact from foreign currency rate fluctuations and additional manufacturing expenses related to expansion of new therapies; this wording is removed in the newer filing.
- Older filing contains a discussion of diluted earnings per share increase for the three months ended March 31, 2026, which is absent from the newer filing.
- Older filing contains separate sections titled "Transcatheter Mitral and Tricuspid Therapies Sales" and "Surgical" with narrative discussions of TMTT and Surgical product sales for the three months ended March 31, 2026; these sections are not present in the newer filing (the newer filing's provided text is truncated at the start of the TAVR section and does not include equivalent detailed sections).
- Older filing contains a section titled "Gross Profit" with narrative for the three months ended March 31, 2026; this section is not present in the provided newer filing text.
- Older filing's TAVR section discusses foreign currency impact of $32.0 million for the three months ended March 31, 2026; in the newer filing the corresponding three-month TAVR foreign currency impact is stated as $8.4 million for the three months ended June 30, 2026.
- Reworded:
- Financial Highlights section: Older filing states net sales for the first three months of 2026 were $1.6 billion, an increase of $235.9 million compared to the first three months of 2025; newer filing states net sales for the first six months of 2026 were $3.4 billion, an increase of $444.7 million compared to the first six months of 2025.
- Financial Highlights section: Older filing discusses gross profit and diluted EPS for the three months ended March 31, 2026; newer filing discusses gross profit and diluted EPS for the six months ended June 30, 2026.
- Regional sales table: Older filing reports three-month data for March 31 periods (2026 vs 2025); newer filing reports both three-month data for June 30 and six-month data.
- Product group sales table: Older filing reports three-month data for March 31 periods; newer filing reports both three-month data for June 30 and six-month data.
- TAVR section: Older filing says foreign currency increased net sales outside the U.S. by $32.0 million for the three months ended March 31, 2026; newer filing says foreign currency increased net sales outside the U.S. by $8.4 million for the three months ended June 30, 2026 and $40.4 million for the six months.
- Overview paragraph: Older filing says "We conduct operations worldwide and are managed in the following geographical regions"; newer filing says "We conduct operations worldwide that are managed in the following geographical regions".
- Overview paragraph: Older filing states only that the results of Autus have been included from the date of acquisition; newer filing adds the Consolidated VIE to this sentence.
- FDA approval in January 2026: Older filing says "United States Food and Drug Administration approval"; newer filing says "United States Food and Drug Administration ("FDA") approval".
- Notes:
- The provided newer filing text is truncated at the start of the TAVR section ("Transcath"), so any changes to sections appearing after that cut-off in the newer filing (such as TMTT, Surgical, or Gross Profit sections) cannot be compared.
- The older filing contains a negative 0.3 percentage point foreign currency impact figure that appears to be cut off mid-sentence in the provided source text, so the removal of related wording may be partially incomplete.
Risk Factors
- Added:
- In the filing dated 2026-08-04, a new exhibit 10.2 is listed: 'Amended and Restated Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program' (incorporated by reference to Exhibit 10.1 in the 8-K filed May 8, 2026).
- In the filing dated 2026-08-04, a new paragraph under Item 5 discloses that on July 28, 2026, Bernard J. Zovighian, CEO and Director, entered into a Rule 10b5-1 trading plan for potential sale of 145,696 shares commencing November 9, 2026, terminating on the earlier of May 14, 2027 or the date all shares are sold.
- In the filing dated 2026-08-04, signatures reflect Theodora Mistras as Corporate Vice President, Chief Financial Officer and Principal Financial Officer.
- Removed:
- In the filing dated 2026-05-06, signatures reflected Scott B. Ullem as Corporate Vice President, Chief Financial Officer and Principal Financial Officer; these signatures do not appear in the filing dated 2026-08-04.
- Reworded:
- The issuer purchases of equity securities table changed: filing dated 2026-05-06 includes periods January 1, 2026 through March 31, 2026; filing dated 2026-08-04 includes periods April 1, 2026 through June 30, 2026.
- Item 5 changed the referenced quarter: filing dated 2026-05-06 says 'During the first quarter of 2026'; filing dated 2026-08-04 says 'During the second quarter of 2026'.
- The signing date of the Form 10-Q changed from May 6, 2026 (filing dated 2026-05-06) to August 4, 2026 (filing dated 2026-08-04).
- Notes:
- The provided texts include the entirety of the source content as supplied; the Risk Factors section itself in both filings states that there have been no material changes to Risk Factors from the Annual Report on Form 10-K for fiscal year ended December 31, 2025.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 11 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
- Last 30 days · read to 2026-10-050 buys · 2 sells ($107186) — 1 selling insider
- Last 90 days · read to 2026-10-050 buys · 11 sells ($5M) — 6 selling insiders
- Last 180 days · read to 2026-10-050 buys · 26 sells ($11M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-08. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EW's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 6 matched disclosures for EW from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding EW as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 102,386,851
- Reported value $9,261,914,396
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about EW's institutional holders → See what each manager we track holds →
Short interest (FINRA)
EW had 9,088,401 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
EW had 1.58% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.15 days to cover at the same settlement.
- Reported short interest (shares) 9,088,401
- Short interest (% of shares outstanding) 1.58%
- Prior settlement (shares) 9,022,064
- Reported change 0.74%
- Days to cover (reported) 3.15
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EW vs…
Edwards Lifesciences is found in…
Frequently asked questions
What does Edwards Lifesciences (EW) do?
Edwards Lifesciences focuses on innovations for structural heart disease and critical care monitoring. The company specializes in developing technologies for patients with cardiovascular disease, including transcatheter heart valve replacement and repair technologies.
What sector is Edwards Lifesciences (EW) in?
Edwards Lifesciences (EW) is classified in the Health Care sector. Its industry is medical devices - cardiovascular. It trades on NYSE.
Who are Edwards Lifesciences's (EW) competitors?
Notable peers of Edwards Lifesciences (EW) include Medtronic, Abbott Laboratories, Boston Scientific and Johnson & Johnson. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in EW?
Yes — we hold 6 matched STOCK Act disclosures for EW from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Edwards Lifesciences (EW) overbought or oversold right now?
Edwards Lifesciences (EW) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EW come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.